Loading…
← CockpitCompetitor Analysis › 1167.HK Jacobio Pharmaceuticals Group Co., Ltd.Open in the cockpit ↗

Jacobio Pharmaceuticals Group Co., Ltd.1167.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum weak 30
Mkt cap
$404M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$498,721
20-day average traded
Fwd P/E
5.7×
forward earnings
ROIC−WACC
n/a
WACC 10.3%
Hurdle
+17 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · HKDHK$4.10
1D+0.9%
1W-14.6%
1M-22.4%
3M-19.4%
6M-23.6%
YTD-35.6%
1Y-40.2%
ATR %6.4%
52w lowhigh55.9% off high

What Jacobio Pharmaceuticals does

Employees: 196

Jacobio Pharmaceuticals at a glance

Size Jacobio Pharmaceuticals (1167.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $404M, the 805th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.10 on 18 Nov 2026.

Performance Over six months the shares fell 23.6%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 286.2% over the last twelve months (peer median +9.6%); the operating margin is 68.0% (peer median -7.2%).

Valuation It trades at 5.7× forward earnings against a peer median of 26.2× (cheapest of 7).

Price implies For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is -36%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20261167.HK 77Peer median 77
Six months, rebased to 100: Jacobio Pharmaceuticals against the median of its 20 peers (local-currency closes).

Jacobio Pharmaceuticals financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$842MHK$58.0MHK$169MHK$70.2MHK$111M
Revenue growth—-66%+141%-37%—
Gross profitHK$795MHK$32.7MHK$140M-HK$23.4MHK$62,795
EBITDAHK$598M-HK$160M-HK$207M-HK$432M-HK$537M
Net incomeHK$589M-HK$158M-HK$169M-HK$397M-HK$432M
Free cash flowHK$622M-HK$208M-HK$55.3M-HK$423M-HK$362M
Capital expenditureHK$1.76MHK$1.81MHK$13.1MHK$42.7MHK$19.2M
Total debtn/aHK$359MHK$275MHK$296MHK$166M

Quarterly statements and history in the cockpit →

Jacobio Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%688098337869982480300683688238EPRX688163456160CADL476830688687PNV68831730096665476712ALEC2509PRTA1167.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Jacobio Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×150×688687PNV6547671225091167.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jacobio Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%6998688687PNV68831767121167.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jacobio Pharmaceuticals is the large dot.

Jacobio Pharmaceuticals competitors and peer comparison

How Jacobio Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jacobio Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure1167.HKPeer medianRank in peer set
1-month return-22.4%-11.3%2nd lowest of 21
6-month return-23.6%-22.0%9th lowest of 21
Distance from 52-week high-55.9%-40.6%6th lowest of 21
Revenue growth (TTM)+286.2%+9.6%3rd highest of 17
Operating margin68.0%-7.2%highest of 17
Forward P/E5.7×26.2×cheapest of 7
Growth the price implies (Req g, 7 yrs)-18.8%4.6%2nd least demanding of 7
Growth delivered (Del g)-36.1%+37.6%2nd lowest of 6
Hurdle (Req g minus delivered)+17.4 pp+14.3 pp3rd most demanding of 6
EV / EBITDA2.7×5.2×cheapest of 4
Net debt / EBITDA-2.6×-2.1×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%n/an/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/a26.2×n/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%n/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%16.2×36.6%+8.9%
Polynovo PNV.AXAustralia$388M-34%+13%5%84.0×51.9%+37.6%
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%n/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%26.2×5.3%+70.5%
Alector ALECUnited States$383M+21%+151%25%n/an/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%10.2×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%n/an/an/a

Questions

Which companies are Jacobio Pharmaceuticals's closest peers?
The cockpit's peer set: Shanghai Shen Lian Biomedical (688098.SS), Hanx Biopharmaceuticals (Wuhan) (3378.HK), Edding Genor (6998.HK), Beijing Luzhu Biotechnology (2480.HK), Wuhan Hiteck Biological Pharma (300683.SZ), Shanghai Obio Technology (Group) (688238.SS), Eupraxia Pharmaceuticals (EPRX.TO), Shanghai Serum Bio-Technology (688163.SS).
Is Jacobio Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 5.7× against a peer median of 26.2×, cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about -19% a year for seven years (Req g). Recent delivered growth is -36%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jacobio Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -23.6% against -22.0% for the median peer; over one year -40.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.